Sanofi的哮喘药物Amlitelimab显示前景光明,导致进一步试验和探索相关的呼吸道治疗。 Sanofi's asthma drug amlitelimab shows promise, leading to further trials and exploration of related respiratory treatments.

萨诺菲在呼吸道药物开发方面取得了长足的进步。 Sanofi has made strides in its respiratory drug development. 治疗哮喘的Amlimab(Amlitelimab)为某些哮喘病人展示了可喜的结果,尽管主要目标尚未完全实现。 Amlitelimab, an asthma treatment, showed promising results for certain asthma patients, though primary goals were not fully met. 该公司计划继续进行阿米利利马布的第三阶段试验,并正在探索其他药物,即lunsekimig和 itepekimab,用于治疗包括COPD和慢性鼻炎在内的更广泛的呼吸系统疾病,今年和2026年将开始新的研究. The company plans to move forward with phase 3 trials for amlitelimab and is exploring other drugs, lunsekimig and itepekimab, for broader respiratory conditions including COPD and chronic rhinosinusitis, with new studies starting this year and in 2026.